explore -WSS

explore

author：leisure time 2025-09-27 18:37:25 - browse：476

Duchenne muscular dystrophy is a devastating disease and, until very recently, was one without much hope. When Hawken Miller was diagnosed at age 5, the physician told his parents to enjoy the time they had with him, as there wouldn’t be much. Over 20 years later, Miller is a journalist and content strategist for CureDuchenne, an organization started by his mother when he was diagnosed, and new treatment is on the horizon.

Last month, the FDA approved a new gene therapy from Sarepta Therapeutics that will provide hope for many patients and families. The new drug, however, has its limitations — it’s only approved for children age 4-5, for example. Miller joined the podcast to discuss how this drug may change lives, what more needs to happen, and what his personal experience has been living with Duchenne.

“For the older boys, we’re running up against the clock a little bit with what we’re able to do and what we’re not able to do,” Miller said. “And if we’re able to try anything that could possibly help, I think most people would like the opportunity to do that.”

The conversation is based off his recent First Opinion, “The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Bernie Sanders is gearing up to subpoena pharma CEOs

WSS

Bernie Sanders is gearing up to subpoena pharma CEOs

RaDonda Vaught case: a double standard for nurses, physicians

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

A new study asks: Are we harming blood donors by taking blood?

Can food be medicine? And other questions about a new push

leisure time

explore

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

A new study asks: Are we harming blood donors by taking blood?

In age of alternative facts, a scholarly course on calling out crap

Can food be medicine? And other questions about a new push

Medicare proposal to cover medical devices draws a mixed reaction

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Jerome Adams on the need for new antivirals for Covid

Zyn nicotine pouches become unlikely player in latest culture war

Guidelines to prevent youth baseball injuries need more muscle

Doctor appointment wait times are getting worse

focus

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

Medicare Advantage insurers face 0.2% cut to 2025 payments

Bernie Sanders is gearing up to subpoena pharma CEOs

10 reasons why health care startups fail

These geoengineering technologies could help combat the climate crisis, scientists say

Boston competes with Raleigh

leisure time

hotspot

hotspot

explore